T. Rowe Price Associates, Inc. 13D and 13G filings for Ultragenyx Pharmaceutical Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 10:03 am Sale | 2023-12-31 | 13G | Ultragenyx Pharmaceutical Inc. RARE | T. Rowe Price Associates, Inc. | 3,453,460 4.200% | -642,928 (-15.69%) | Filing |
| 2023-02-14 12:38 pm Sale | 2022-12-31 | 13G | Ultragenyx Pharmaceutical Inc. RARE | T. Rowe Price Associates, Inc. | 4,096,388 5.800% | -1,579,610 (-27.83%) | Filing |
| 2022-08-10 2:56 pm Sale | 2022-07-31 | 13G | Ultragenyx Pharmaceutical Inc. RARE | T. Rowe Price Associates, Inc. | 5,675,998 8.100% | -5,849,091 (-50.75%) | Filing |
| 2022-02-14 2:34 pm Purchase | 2021-12-31 | 13G | Ultragenyx Pharmaceutical Inc. RARE | T. Rowe Price Associates, Inc. | 11,525,089 16.900% | 2,054,597 (+21.69%) | Filing |
| 2021-02-16 12:23 pm Purchase | 2020-12-31 | 13G | Ultragenyx Pharmaceutical Inc. RARE | T. Rowe Price Associates, Inc. | 9,470,492 14.300% | 2,851,572 (+43.08%) | Filing |